155 related articles for article (PubMed ID: 28932295)
1. Expression of MDM2 mRNA, MDM2, P53 and P16 Proteins in Urothelial Lesions in the View of the WHO 4
Hammam O; Magdy M; Badawy M; Osili KA; Kholy AE; LeitHy TE
Open Access Maced J Med Sci; 2017 Aug; 5(5):578-586. PubMed ID: 28932295
[TBL] [Abstract][Full Text] [Related]
2. Altered p53/p16 expression is linked to urothelial carcinoma progression but largely unrelated to prognosis in muscle-invasive tumors.
Schallenberg S; Plage H; Hofbauer S; Furlano K; Weinberger S; Bruch PG; Roßner F; Elezkurtaj S; Kluth M; Lennartz M; Blessin NC; Marx AH; Samtleben H; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke T; Hallmann S; Koch S; Adamini N; Minner S; Simon R; Sauter G; Horst D; Klatte T; Schlomm T; Zecha H
Acta Oncol; 2023 Dec; 62(12):1880-1889. PubMed ID: 37938166
[TBL] [Abstract][Full Text] [Related]
3. Clinico-Pathological Features and Immunohistochemical Comparison of p16, p53, and Ki-67 Expression in Muscle-Invasive and Non-Muscle-Invasive Conventional Urothelial Bladder Carcinoma.
Hasan A; Mohammed Y; Basiony M; Hanbazazh M; Samman A; Abdelaleem MF; Nasr M; Abozeid H; Mohamed HI; Faisal M; Mohamed E; Ashmawy D; Tharwat M; Morsi DF; Farag AS; Ahmed EM; Aly NM; Abdel-Hamied HE; Salama DEA; Mandour E
Clin Pract; 2023 Jul; 13(4):806-819. PubMed ID: 37489422
[TBL] [Abstract][Full Text] [Related]
4. Strong correlation of basement membrane degradation with p53 inactivation and/or MDM2 overexpression in superficial urothelial carcinomas.
Ozdemir E; Kakehi Y; Okuno H; Habuchi T; Okada Y; Yoshida O
J Urol; 1997 Jul; 158(1):206-11. PubMed ID: 9186361
[TBL] [Abstract][Full Text] [Related]
5. Profiles of the 2 INK4a gene products, p16 and p14ARF, in human reference urothelium and bladder carcinomas, according to pRb and p53 protein status.
Le Frère-Belda MA; Gil Diez de Medina S; Daher A; Martin N; Albaud B; Heudes D; Abbou CC; Thiery JP; Zafrani ES; Radvanyi F; Chopin D
Hum Pathol; 2004 Jul; 35(7):817-24. PubMed ID: 15257544
[TBL] [Abstract][Full Text] [Related]
6. MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1.
Olsson H; Hultman P; Rosell J; Söderkvist P; Jahnson S
BMC Urol; 2013 Jan; 13():5. PubMed ID: 23356517
[TBL] [Abstract][Full Text] [Related]
7. Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and urothelial tumors.
Li L; Xu H; Spaulding BO; Cheng L; Simon R; Yao JL; di Sant'Agnese PA; Bourne PA; Huang J
Hum Pathol; 2008 Aug; 39(8):1205-11. PubMed ID: 18547613
[TBL] [Abstract][Full Text] [Related]
8. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.
Osman I; Scher HI; Zhang ZF; Pellicer I; Hamza R; Eissa S; Khaled H; Cordon-Cardo C
Clin Cancer Res; 1997 Apr; 3(4):531-6. PubMed ID: 9815716
[TBL] [Abstract][Full Text] [Related]
9. p16(INK4a) /Ki-67 dual labelling as a marker for the presence of high-grade cancer cells or disease progression in urinary cytopathology.
Piaton E; Advenier AS; Carré C; Decaussin-Petrucci M; Mege-Lechevallier F; Ruffion A
Cytopathology; 2013 Oct; 24(5):327-34. PubMed ID: 23003335
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implications of aberrations in p16/pRb pathway in urothelial bladder carcinomas: a multivariate analysis including p53 expression and proliferation markers.
Korkolopoulou P; Christodoulou P; Lazaris A; Thomas-Tsagli E; Kapralos P; Papanikolaou A; Kalliteraki I; Davaris P
Eur Urol; 2001 Feb; 39(2):167-77. PubMed ID: 11223676
[TBL] [Abstract][Full Text] [Related]
11. Alterations of p53 and Rb Pathways Are Associated with High Proliferation in Bladder Urothelial Carcinomas.
Goussia AC; Papoudou-Bai A; Charchanti A; Kitsoulis P; Kanavaros P; Kalef-Ezra J; Stefanou D; Agnantis NJ
Anticancer Res; 2018 Jul; 38(7):3985-3988. PubMed ID: 29970521
[TBL] [Abstract][Full Text] [Related]
12. p16 INK4a overexpression and p16/Ki-67 dual labeling versus conventional urinary cytology in the evaluation of urothelial carcinoma.
Piaton E; Carré C; Advenier AS; Decaussin-Petrucci M; Mège-Lechevallier F; Lantier P; Granier G; Ruffion A
Cancer Cytopathol; 2014 Mar; 122(3):211-20. PubMed ID: 24302621
[TBL] [Abstract][Full Text] [Related]
13. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Henke C; Korabiowska M; Schlott T; Zimmerman B; Kunze E
Anticancer Res; 2004; 24(2B):1011-23. PubMed ID: 15161057
[TBL] [Abstract][Full Text] [Related]
14. IMP3 expression in urothelial carcinomas of the urinary bladder.
Ozdemir NO; Türk NS; Düzcan E
Turk Patoloji Derg; 2011 Jan; 27(1):31-7. PubMed ID: 21469424
[TBL] [Abstract][Full Text] [Related]
15. Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas.
Kakehi Y; Ozdemir E; Habuchi T; Yamabe H; Hashimura T; Katsura Y; Yoshida O
Jpn J Cancer Res; 1998 Feb; 89(2):214-20. PubMed ID: 9548450
[TBL] [Abstract][Full Text] [Related]
16. Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions.
Schwarz S; Rechenmacher M; Filbeck T; Knuechel R; Blaszyk H; Hartmann A; Brockhoff G
J Clin Pathol; 2008 Mar; 61(3):272-7. PubMed ID: 17693577
[TBL] [Abstract][Full Text] [Related]
17. p16(INK4a) overexpression is not linked to oncogenic human papillomaviruses in patients with high-grade urothelial cancer cells.
Piaton E; Casalegno JS; Advenier AS; Decaussin-Petrucci M; Mege-Lechevallier F; Ruffion A; Mekki Y
Cancer Cytopathol; 2014 Oct; 122(10):760-9. PubMed ID: 25069600
[TBL] [Abstract][Full Text] [Related]
18. p16ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situ.
Yin M; Bastacky S; Parwani AV; McHale T; Dhir R
Hum Pathol; 2008 Apr; 39(4):527-35. PubMed ID: 18234280
[TBL] [Abstract][Full Text] [Related]
19. p16 expression in urothelial carcinoma: Experience from a tertiary care center in coastal South India.
Sachdeva S; Suresh PK; Basavaiah SH; Sahu KK; Sreeram S; Kini H; Kini JR; Pinto AC
J Cancer Res Ther; 2023; 19(5):1330-1334. PubMed ID: 37787303
[TBL] [Abstract][Full Text] [Related]
20. Tumor markers of bladder cancer: the schistosomal bladder tumors versus non-schistosomal bladder tumors.
Abdulamir AS; Hafidh RR; Kadhim HS; Abubakar F
J Exp Clin Cancer Res; 2009 Feb; 28(1):27. PubMed ID: 19243595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
